The method of claim 12, wherein the drug is polyadenylate polymerase, cleavage and polyadenylation specificity factor (CPSF), or a poly(A) binding protein.Ģ0. The method of claim 12, wherein the drug is an entity that increases or decreases 3′ polyadenylation of the gRNA.ġ9. The method of claim 12, wherein the drug is an entity that alters the, three dimensional, secondary, tertiary, or quaternary structure, of the Cas9 molecule or the gRNA.ġ8. The method of claim 12, wherein the drug is an entity that attaches a moiety to the Cas9 molecule or the gRNA.ġ7. The method of claim 12, wherein the drug is an entity that breaks a covalent or non-covalent bond in the Cas9 molecule or the gRNA.ġ6.

The method of claim 12, wherein the drug is an entity that alters the amount, distribution, or structure of the Cas9 molecule or the gRNA.ġ5. The method of claim 12, wherein the drug is an entity that alters enzymatic activity, transcriptional activity, or translational activity of the Cas9 molecule or the gRNA.ġ4. pyogenes Cas9 molecule, and a first guide RNA (gRNA) and administering a drug that binds to the Cas9 molecule or the gRNA that activates or inhibits activity of the Cas9 molecule or the gRNA.ġ3. A method of treating a subject, the method comprising: altering a eukaryotic cell or a target nucleic acid of a eukaryotic cell by contacting the eukaryotic cell or target nucleic acid of the eukaryotic cell with a first nucleic acid encoding a Cas9 molecule, wherein the Cas9 molecule is an S. The composition or kit of claim 1, wherein the inhibitor is a siRNA, a sh RNA, a ribozyme, an antisense-oligonucleotide, an antibody, or an aptamer.ġ2. The composition or kit of claim 1, wherein the drug is an inhibitor of a transcription factor, a post-translational modification enzyme, or a post-transcriptional modification enzyme.ġ1. The composition or kit of claim 1, wherein the drug is inhibitor of DNA binding 1 (ID1), inhibitor of DNA binding 2 (ID2), inhibitor of DNA binding 3 (ID3), or inhibitor of DNA binding 4 (ID4).ġ0. The composition or kit of claim 1, wherein the drug is polyadenylate polymerase, cleavage and polyadenylation specificity factor (CPSF), or a poly(A) binding protein.ĩ. The composition or kit of claim 1, wherein the drug is an entity that increases or decreases 3′ polyadenylation of the gRNA.Ĩ.

The composition or kit of claim 1, wherein the drug is an entity that alters the, three dimensional, secondary, tertiary, or quaternary structure, of the Cas9 molecule or the gRNA.ħ. The composition or kit of claim 1, wherein the drug is an entity that attaches a moiety to the Cas9 molecule or the gRNA.Ħ. The composition or kit of claim 1, wherein the drug is an entity that breaks a covalent or non-covalent bond in the Cas9 molecule or the gRNA.ĥ. The composition or kit of claim 1, wherein the drug is an entity that alters the amount, distribution, or structure of the Cas9 molecule or the gRNA.Ĥ. The composition or kit of claim 1, wherein the drug is an entity that alters enzymatic activity, transcriptional activity, or translational activity of the Cas9 molecule or the gRNA.ģ. pyogenes Cas9 molecule a nucleic acid encoding a first guide RNA (gRNA) molecule and a drug that binds to the Cas9 molecule or the gRNA that activates or inhibits activity of the Cas9 molecule or the gRNA.Ģ. A composition or kit comprising: a nucleic acid encoding a Cas9 molecule, wherein the Cas9 molecule is an S.

Aplf clover configurator